Affirma Biotech

Executive Summary

Affirma Biotech is a preclinical-stage biotech company headquartered in Barcelona, Spain, focused on developing novel, orally available small molecule immunotherapeutics for severe respiratory infections, including influenza and community-acquired pneumonia. The company's host-directed therapy approach aims to restore immune function in at-risk populations, potentially reducing hospitalization and improving outcomes. Founded in 2018, Affirma operates in the small molecules category and is privately held. As a preclinical entity, it has no approved products or disclosed funding rounds, but its platform targets an urgent unmet medical need in respiratory infections, especially relevant in the post-pandemic landscape.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human Phase 1 trial30% success
• Q3 2026Publication of IND-enabling preclinical data in a peer-reviewed journal50% success
• Q2 2027Partnership or licensing deal with a larger pharma company for respiratory franchise20% success